

Diseas	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
BREAST	S1007	Breast,Adj,N1,Endocrine+/-Chemo	15-JAN-11	400	198
	S0500	Brst,Adv,CTC,mntain v chnge tx	01-OCT-06	201	85
	S0800	Brst,Neoadj nabPAC+/-Bev->AC+G	01-APR-10	220	86
	B39	Stg 0-2, whole vs partial RT	22-MAR-05	300	133
	B47	Chemo vs Chemo + Trastuzumab	07-JAN-11	314	152
	C40503	EndocrineTxCombo w/AntiVEGF Tx	22-MAY-08	172	79
	C40601	NeoAdj, Her-2+, Pac+Trast or Lap	08-DEC-08	151	83
	C40603	Carb/Bev+Neoadj Pac, then AC/EC	21-MAY-10	198	104
	C70301	QOLEmployInformCareCost Analysis	24-OCT-05	0	1
	E1105	Adv, Trastuzumab +/- Bev	21-NOV-07	102	26
	E2108	Early Local Tx for Int Prim Tum	28-FEB-11	0	83
	E3108	CYP2D6 Activity&SingleAgTamox	08-OCT-10	124	49
	IBC24-02	Ovar Ftn suppress/premeno	04-AUG-03	234	99
	JMA27B	5yr Adj Anast vs Exemestrane	24-APR-06	36	10
	MA32	Metformn vs Placebo	08-JUL-10	0	106
	N063D	ALTTO	15-FEB-08	278	116
	N0733	Her2+, Cap + Lap +/- IMC-A12	30-JUL-08	186	76
	PACCT-1	Assess of Ca Clinical Tests	24-APR-06	410	202
GI	S1005	Gastric/GEJ, Adv, MK-2206	01-JAN-11	149	57
	S0518	CARCINOID,ADV,OCTREO/ALPHA/BEV	01-DEC-07	221	88
	S0713	Rect,Stg2-3,Ox/Cape/Cet+RT->SRG	01-FEB-09	155	44
	S0809	EHCC,Adj,Cape+Gem==>Cape+RT	01-DEC-08	183	75
	C80405	GI,Met,FOLFOX/FIRI,Bev,Cetux	26-SEP-05	353	180
	C80702	Adj FOLFOX+Celecoxib or Placebo	22-JUN-10	399	181
	C80802	Soraf+Doxorubicin vs Sorafenib	22-FEB-10	0	46
	E1208	Chemo Soraf. in Unresect HCC	09-NOV-09	140	73
	R0848	Panc, Adj, Erlotinib v ChemoRT	08-DEC-09	0	90
	R1010	Trastuz + Tri Tx of HER2-Overex	07-JAN-11	0	47
GU	S1011	Blad, Standard vs Extended LND	01-AUG-11	5	11
	S1014	Pros, Mets, Abi Acetate	09-AUG-11	191	60
	S0337	Blad, Instill Gem vs Saline	15-JUL-07	116	37
	S0925	Andro Dep w/IMC vs. Andro Dep	15-DEC-10	183	65
	S0931	EVEREST	01-APR-11	310	119
	C70807	MEAL Study	21-JAN-11	57	28
	C90202	Pros,Bone mets,Zoledronic acid	15-JAN-04	118	58
	C90203	Pros, Surgery +/- Neoadj Chemo	22-DEC-06	173	75

Diseas	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
GU	C90601	Trans cell, blind bev vs placebo	07-AUG-09	288	128
	E2805	Renal, Adj Sunitib v Sorafinib	08-MAY-06	354	143
	E3805	CHAARTED	08-AUG-06	136	75
	PR11	Pros, Local, Watch vs Active Tx	15-JUL-07	40	18
	R0415	Hypofrac v Conv 3D-CRG/IMRT	24-APR-06	0	37
	R0521	AS+RT vs AS+RT+Chemo	22-DEC-05	129	59
	R0524	Pac + Trastuzumab vs Pac alone	08-DEC-06	85	27
LEUK	S0535	APL,High Risk, ATRA/arsenic/GO	15-NOV-07	130	52
	S0703	AML, age 60+, Azacitidine G.O.	01-DEC-08	163	53
	S0805	Ph+ ALL, Dasatinib/CVAD +/- BMT	01-SEP-09	93	39
	S0910	Rel ph-,B-ALL,Epratuzumab+Cy+Clo	15-AUG-10	119	35
	S0919	Rel AML: Pravastatin+Ida+Ara-C	15-AUG-09	113	36
	C10403	ALL <40 yrs-Ped,Chemo. Regimen	15-JAN-08	142	59
	C10404	CLL, Flu/Rituxan combinations	15-MAR-09	121	55
	E1908	Tx of PCL Leuk w/Alemtuz, Ritux	22-OCT-10	45	22
	E2905	MDS, Len vs Len + Epo	09-FEB-09	148	83
LUNG	S0709	NSCLC, Adv, PRO+, OSI-774+-Chemo	01-DEC-08	166	64
	S0802	ESCLC,Topotecan+/-AVE0005,PhII	15-MAY-09	256	97
	S0819	NSCLC, ADV, CHEMO/BEV +/-CET	15-JUL-09	336	144
	S0905	Mesothem,cediranib+chemo,PhI/II	15-MAR-10	85	34
	C140503	NSCL, Lobect v Sublobar resect	09-JUL-07	84	50
	C30610	SCLC, Thoracic RT	21-MAR-08	183	98
	C30801	Selective COX-2 Inhibition	22-JUL-10	127	68
	E1505	Stg IB-IIIA chemo +/- Bev	22-JUN-07	422	208
	N107C	SRS vs WBRT on Resected Met Dz	08-JUL-11	23	5
LYMPH	S1001	DLBCL, I-II, PET-Adapted Therapy	15-JUL-11	100	18
	S1106	NHL, Adv, R-HCVAD/R-Benda+PBSCT	01-OCT-11	59	12
	S1108	NHL, Relapsed PTCL, MLN8237	28-OCT-11	57	12
	S0806	NHL, Adv, R-CHOP + SAHA	15-NOV-10	160	39
	S0816	HD, Adv, PET-Adapted Therapy	01-JUL-09	274	107
	C50303	R-CHOP v EPOCH-R	15-SEP-06	120	71
	C50604	Resp-Adapt Chemo Pos Emiss Tomo	22-JUL-10	0	56
	CTN0701	Relapsed follic, allo transplant	23-FEB-09	34	9
MELAN	E1609	Adj Ipil AntiCTLA4 vs Interferon	08-JUN-11	307	120

Disease Site	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
MELAN	E2607	Dasatinib in KIT+ pts w/Melanoma	22-NOV-11	18	19
MMYEL	S0777	MM, Len Dex +/- Bortezomib	01-APR-08	232	88
	S0833	Frontline MM, Total Therapy III	15-MAR-11	28	8
	E3A06	Lenalidomide vs Observation	08-NOV-10	116	52
	E4A08	MDex vs BMDex in untx pts w/AL	22-NOV-10	54	28
PREV	S0812	Breast, Prev, Vit D vs Placebo	01-NOV-11	92	25
SXQOL	S0927	Omega-3-Fatty Acid AI Joint Pain	01-FEB-12	34	9